PDGFRB and neoplasm: Pazopanib is a novel, orally available, multitargeted, TKI targeting several tumor and tumor environment factors with high affinity against vascular endothelial growth factor receptor (VEGFR)1, VEGFR2, and VEGFR3 and low affinity against platelet-derived growth factor receptor (PDGFR)α, PDGFRβ, fibroblast growth factor receptor (FGFR)1, FGFR2, and stem cell factor receptor (c-Kit) [15].